申请人:Consiglio Nazionale delle Ricerche
公开号:US05001147A1
公开(公告)日:1991-03-19
The alkylangelicins according to the invention are obtained starting from an umbelliferone, in which the 6-position is already substituted by an alkyl group; in such a way the 7-allyloxy or 7-acyloxy umbelliferone intermediates can form by transposition of the allyl or acyl group only the 8-allyl and 8-acyl derivatives, and therefore the presence, even in traces, of psoralens is absolutely excluded in the subsequent synthetic steps. The 6-alkylangelicins thus obtained are particularly usable for the photochemotherapy of psoriasys and of other skin diseases characterized by cellular hyperproliferation, as well as for the photochemotherapy of vitiligo and of alopecia aerata.
本发明的烷基天使光素可从已经被烷基取代的香豆素出发获得;通过这种方式,7-烯丙氧基或7-酰氧基香豆素中间体可以通过烯丙基或酰基基团的转位形成仅是8-烯丙基和8-酰基衍生物,因此即使是微量的苦参素在随后的合成步骤中也是绝对不会存在的。因此,所获得的6-烷基天使光素特别适用于银屑病和其他细胞增殖性皮肤疾病的光化学疗法,以及白癜风和斑秃的光化学疗法。